These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30887250)

  • 1. A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors.
    Rosen LS; Wesolowski R; Baffa R; Liao KH; Hua SY; Gibson BL; Pirie-Shepherd S; Tolcher AW
    Invest New Drugs; 2020 Feb; 38(1):120-130. PubMed ID: 30887250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors.
    Shapiro GI; Vaishampayan UN; LoRusso P; Barton J; Hua S; Reich SD; Shazer R; Taylor CT; Xuan D; Borghaei H
    Invest New Drugs; 2017 Jun; 35(3):315-323. PubMed ID: 28070718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors.
    King GT; Eaton KD; Beagle BR; Zopf CJ; Wong GY; Krupka HI; Hua SY; Messersmith WA; El-Khoueiry AB
    Invest New Drugs; 2018 Oct; 36(5):836-847. PubMed ID: 29333575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
    Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
    Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer.
    Pegram MD; Hamilton EP; Tan AR; Storniolo AM; Balic K; Rosenbaum AI; Liang M; He P; Marshall S; Scheuber A; Das M; Patel MR
    Mol Cancer Ther; 2021 Aug; 20(8):1442-1453. PubMed ID: 34045233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer.
    Kim SB; Meric-Bernstam F; Kalyan A; Babich A; Liu R; Tanigawa T; Sommer A; Osada M; Reetz F; Laurent D; Wittemer-Rump S; Berlin J
    Target Oncol; 2019 Oct; 14(5):591-601. PubMed ID: 31502117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors.
    Garrido-Laguna I; Krop I; Burris HA; Hamilton E; Braiteh F; Weise AM; Abu-Khalaf M; Werner TL; Pirie-Shepherd S; Zopf CJ; Lakshminarayanan M; Holland JS; Baffa R; Hong DS
    Int J Cancer; 2019 Oct; 145(7):1798-1808. PubMed ID: 30680712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
    Shitara K; Iwata H; Takahashi S; Tamura K; Park H; Modi S; Tsurutani J; Kadowaki S; Yamaguchi K; Iwasa S; Saito K; Fujisaki Y; Sugihara M; Shahidi J; Doi T
    Lancet Oncol; 2019 Jun; 20(6):827-836. PubMed ID: 31047804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer.
    Segal NH; He AR; Doi T; Levy R; Bhatia S; Pishvaian MJ; Cesari R; Chen Y; Davis CB; Huang B; Thall AD; Gopal AK
    Clin Cancer Res; 2018 Apr; 24(8):1816-1823. PubMed ID: 29549159
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study.
    Meric-Bernstam F; Calvo E; Lee KS; Moreno V; Park YH; Rha SY; Chalasani P; Zhong W; Zhou L; Pirie-Shepherd S; Leung ACF; Curigliano G
    Mol Cancer Ther; 2023 Oct; 22(10):1191-1203. PubMed ID: 37420274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.
    Shapiro GI; Bell-McGuinn KM; Molina JR; Bendell J; Spicer J; Kwak EL; Pandya SS; Millham R; Borzillo G; Pierce KJ; Han L; Houk BE; Gallo JD; Alsina M; Braña I; Tabernero J
    Clin Cancer Res; 2015 Apr; 21(8):1888-95. PubMed ID: 25652454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
    Maitland ML; Sachdev JC; Sharma MR; Moreno V; Boni V; Kummar S; Stringer-Reasor E; Lakhani N; Moreau AR; Xuan D; Li R; Powell EL; Jackson-Fisher A; Bowers M; Alekar S; Xin X; Tolcher AW; Calvo E
    Clin Cancer Res; 2021 Aug; 27(16):4511-4520. PubMed ID: 34083232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
    Hassan R; Blumenschein GR; Moore KN; Santin AD; Kindler HL; Nemunaitis JJ; Seward SM; Thomas A; Kim SK; Rajagopalan P; Walter AO; Laurent D; Childs BH; Sarapa N; Elbi C; Bendell JC
    J Clin Oncol; 2020 Jun; 38(16):1824-1835. PubMed ID: 32213105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
    Krop IE; Beeram M; Modi S; Jones SF; Holden SN; Yu W; Girish S; Tibbitts J; Yi JH; Sliwkowski MX; Jacobson F; Lutzker SG; Burris HA
    J Clin Oncol; 2010 Jun; 28(16):2698-704. PubMed ID: 20421541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors.
    Ferrarotto R; Eckhardt G; Patnaik A; LoRusso P; Faoro L; Heymach JV; Kapoun AM; Xu L; Munster P
    Ann Oncol; 2018 Jul; 29(7):1561-1568. PubMed ID: 29726923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors.
    Naing A; Gainor JF; Gelderblom H; Forde PM; Butler MO; Lin CC; Sharma S; Ochoa de Olza M; Varga A; Taylor M; Schellens JHM; Wu H; Sun H; Silva AP; Faris J; Mataraza J; Cameron S; Bauer TM
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32179633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study.
    Gazzah A; Bedard PL; Hierro C; Kang YK; Abdul Razak A; Ryu MH; Demers B; Fagniez N; Henry C; Hospitel M; Soria JC; Tabernero J
    Ann Oncol; 2022 Apr; 33(4):416-425. PubMed ID: 35026412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors.
    Smith DC; Chugh R; Patnaik A; Papadopoulos KP; Wang M; Kapoun AM; Xu L; Dupont J; Stagg RJ; Tolcher A
    Invest New Drugs; 2019 Aug; 37(4):722-730. PubMed ID: 30591982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.
    Bilusic M; Heery CR; Collins JM; Donahue RN; Palena C; Madan RA; Karzai F; Marté JL; Strauss J; Gatti-Mays ME; Schlom J; Gulley JL
    J Immunother Cancer; 2019 Sep; 7(1):240. PubMed ID: 31488216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors.
    Forero A; Bendell JC; Kumar P; Janisch L; Rosen M; Wang Q; Copigneaux C; Desai M; Senaldi G; Maitland ML
    Invest New Drugs; 2017 Jun; 35(3):298-306. PubMed ID: 28050790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.